Paul has been head of De Brauw's Corporate M&A practice for many years. He has a well-established international corporate practice, representing listed companies, large multinationals and private equity firms, focusing on complex matters and strategic issues. He has handled a wide range of Dutch and cross-border public takeovers, private acquisitions and disposals, auctions and joint ventures, both in the Netherlands and elsewhere. Paul frequently advises on corporate governance aspects and shareholder activism. Paul is an experienced board room advisor and has acted as arbitrator in numerous ICC, AAA and NAI arbitrations. Paul is a trusted advisor to many of De Brauw's clients, and counts among his diverse client base Stellantis, Pfizer, Digital Realty, and Technip Energies.

Paul has been nominated for ‘Best M&A lawyer of the Netherlands’ several times.

Paul’s recent work includes advising:

• Pfizer on the USD 22 billion merger of spin-off Upjohn and Mylan
• Siemens on its EUR 628 million acquisition of Mendix
• CB&I on its USD 6 billion combination with McDermott
• Patheon on the USD 7,2 billion recommended offer by Thermo Fisher
• Strauss Coffee on its EUR 257 million share buyback from TPG
• Fugro on its successful defense against Boskalis
• Patheon on its USD 3 billion IPO on NYSE
• Teva on its unsolicited USD 40 billion approach of Mylan
• Prosensa on the USD 840 million recommended offer by Biomarin
• Temasek on its pre-IPO cornerstone investment in NN Group
• Alliance Data Systems (ADS) on its acquisition of Brand Loyalty
• Telefonica on its acquisition of E-Plus from KPN
• Omnicom on its proposed USD 35 billion merger with Publicis
• CNH Global on its USD 12 billion merger with Fiat Industrial
• Germany on the Airbus shareholder pact with France and Spain